Future growth expectations in sales/revenue/volumes?

HCG aims to grow faster than the market, which is expanding at about 10-11% annually. Mature centers showed adjusted revenue growth of approximately 12% after accounting for operational adjustments. Emerging centers are expected to drive higher incremental growth, with some centers like Kolkata and Mumbai showing strong revenue growth (57% and 17% respectively). Capacity expansions planned (e.g., new 100-bed facility in North Bangalore and additional beds in Indore) will support volume growth without current capacity constraints. Increased ARPOB (Average Revenue per Occupied Bed) is a

Future growth expectations in earnings/operating earnings/profits/EPS?

HCG aims to grow faster than the market, which is growing at about 10-11%, leveraging a strong growth pipeline and existing hospitals. EBITDA margins are targeted around 20%, but may fall short in the next 1-2 quarters due to new centers (Indore, Whitefield) initially pulling margins down. Mature centers have shown steady growth with EBITDA margins around 24%, emerging centers improving with steady EBITDA growth. ARPOB (average revenue per occupied bed) is increasing, driven by emerging centers in bigger cities with more affluent populations, supporting profitability. Investments in ne

Health.GlobalQ3 FY24Healthcare Services

Health.Global Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹669P/E: 216.5Market Cap: ₹10.4K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

HCG aims to grow faster than the market, which is expanding at about 10-11% annually.
Mature centers showed adjusted revenue growth of approximately 12% after accounting for operational adjustments.
Emerging centers are expected to drive higher incremental growth, with some centers like Kolkata and Mumbai showing strong revenue growth (57% and 17% respectively).
Capacity expansions planned (e.g., new 100-bed facility in North Bangalore and additional beds in Indore) will support volume growth without current capacity constraints.
Increased ARPOB (Average Revenue per Occupied Bed) is a key lever for growth, with ARPOB already rising across many centers.
Investments in clinical talent and technology (e.g., radiation machines) are expected to improve volume and revenue mix.
HCG expects continued volume and revenue growth through new center ramp-ups, better service mix, and geographic expansion.

Margin guidance

Category 1

HCG aims to grow faster than the market, which is growing at about 10-11%, leveraging a strong growth pipeline and existing hospitals.
EBITDA margins are targeted around 20%, but may fall short in the next 1-2 quarters due to new centers (Indore, Whitefield) initially pulling margins down.
Mature centers have shown steady growth with EBITDA margins around 24%, emerging centers improving with steady EBITDA growth.
ARPOB (average revenue per occupied bed) is increasing, driven by emerging centers in bigger cities with more affluent populations, supporting profitability.
Investments in new technologies (e.g., radiation machines) and better service mix are expected to improve contribution and gross margins going forward.
Expansion plans include gradual capacity additions in mature centers, maintaining occupancy and revenue growth potential without capacity constraints in next 3-4 years.
Capex maintained around INR 70-75 crores for maintenance; acquisition-driven debt is manageable with improving cash flows projected.

See what Health.Global management said on margin guidance — free account, 30 seconds.

Fundraise plans

- Indore and Nagpur acquisitions were partly funded by debt and partly by internal accruals, leading to a slight increase in net debt this quarter. - Maintenance capex is expected to remain around INR 70-75 crores annually, aside from growth plans. - No explicit mention of any new fundraising through debt or equity in the near term in the transcript. - CFO noted that there was a slight increase in net debt due to acquisitions but no specific plans for new debt raising were shared. - Focus appears to be on internal accruals and controlled capex for expansion. - No indications of equity fundraising or plans to raise fresh capital through issuance mentioned. - Management is focused on growth and operational efficiencies without stating new fundraising. Overall, the company has not announced any current or future fundraising through debt or equity beyond what has already been done for recent acquisitions.

Order book

The transcript provided from Healthcare Global Enterprises Limited does not mention any details about the current or expected order book or pending orders. The discussion largely focuses on operational performance, expansion plans, EBITDA margins, capacity additions, payer mix, ARPOB (average revenue per occupied bed), and future growth strategies. Key highlights related to operations and plans: - Expansion with new facilities like the North Bangalore 100-bed hospital (to be operational in 15-18 months). - Capacity additions in mature centers (e.g., 60 additional beds including Baroda). - Steady improvement in EBITDA margin, targeting ~20%. - Integration and upgrades underway at Indore hospital. - Focus on centers of excellence achieving EBITDA margins around 30%. - Growth plans aligned with expanding capacity and improving revenue mix. No specific references to orderbook or pending orders were disclosed in this call.

See what Health.Global management said on order book — free account, 30 seconds.

Capex plans

Yes

- North Bangalore: Planned state-of-the-art 100-bedded premium facility with expected capital outlay of ~INR90 crores; operational timeline of 15-18 months. - Ahmedabad: Expansion from a 100-bedded to 200-bedded premium hospital; capital investment includes about INR106 crores for this project; already spent INR48 crores. - Whitefield (Bangalore): Stand-alone 25-bedded comprehensive cancer center focusing on women's cancers; planned capex ~INR25 crores. - Indore: Acquired hospital with plans for future capacity expansion by 100 beds (Phase II), with ongoing integration and value creation projects. - Maintenance Capex: Expected around INR70-75 crores annually, excluding growth-related capex. - Total bed additions: Approximately 350 beds to be added over next 3 years including Ahmedabad and Whitefield expansions. These investments align with HCG's growth and market expansion strategy focused on premium cancer care facilities.

Track Health.Global — get its next earnings analysis in your feed

How does Health.Global rank vs peers in Healthcare Services?

Pro feature

ThisHealth.Global

Rev 3Mar 1

See where Health.Global sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Health.Global rank in Healthcare Services?

Compare Health.Global against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Health.Global's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →